CLVS Zooms To New High, FLML Gets Thumbs Up, SNTA Dives, STEM Grows

By RTT News, June 04, 2013, 12:58:00 AM EDT

(RTTNews.com) - AbbVie Inc. ( ABBV ) on Monday announced that its investigational oncology compound ABT-199, developed in partnership with Genentech, has demonstrated potential in treating patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, in a phase I study.

The company's amended clinical trial protocols for studies of ABT-199 in patients with CLL were recently accepted by the FDA and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into later-stage clinical trials in the near future.

ABBV closed Monday's trading 1.57% higher at $43.36.

Biologix Hair Inc. ( BLGX ) rose over 9% on Monday after the company announced that its network has expanded from 196 clinics at the time of inception to 276 clinics through the end of April 2013. During the same period, the number of countries in which clinicians has been contracted has increased from 11 to 37.

BioTime Inc. ( BTX ) has offered to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in "units" with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 per unit. The company expects to raise $9 million in the registered direct offering.

BTX closed Monday's trading at $4.82,up 1.47%. In extended trading, the stock fell 1.66% to $4.74.

Shares of Clovis Oncology Inc. ( CLVS ) surged as much as 136% on Monday after the company reported encouraging results from an ongoing phase I/II monotherapy study of its investigational drug Rucaparib in patients with ovarian cancer.

According to the trial results, Rucaparib demonstrated 89% clinical benefit rate in ovarian cancer patients across all doses. The company noted that the phase II dose has not yet defined and that the maximum tolerated dose has not been reached.

CytRx Corp. ( CYTR ) announced Monday that its drug candidate, Aldoxorubicin, administered at 90% of its single agent dose can be safely delivered in combination with Doxorubicin administered at 50% of its single agent dose to patients with advanced solid tumors. Aldoxorubicin is an improved version of the widely used chemotherapeutic agent Doxorubicin.

Read the original post:
CLVS Zooms To New High, FLML Gets Thumbs Up, SNTA Dives, STEM Grows